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Starting from fl-benzoylpropionic acid we synthesized 3-(aminomethyl)tetralones in which the amino substituent 
was d(N-piperaziny1)-p-fluorobutyrophenone (14), 4benzoylpiperidine (15),4-hydroxy-4phenylpiperidine (16) or 
d(o-methoxypheny1)piperazine (17). The poesible dopamine antagonist activity of theae compounds was investigated 
in both ‘in vitro” and ‘in vivo” experiments. These compounds potently inhibited [3H]spiperone binding to D2 
striatal receptors and moderately inhibited [3H]SCH-23390 binding to D1 striatal receptors (Kis in the nanomolar 
and micromolar ranges, respectively). Apomorphine-induced stereotypies and amphetamine group toxicity were 
antagonized, to different extents, by the compounds under study, with a potency similar to that of haloperidol. 
Interestingly, no catalepsy was observed after administration of the new compounds (2-8 mgfkg). The most active 
compounds ‘in vivo” 14 and 15 poseeaeed two butymphenone pharmacophorea. However, the tetralone moiety appeared 
not critical for their antidopaminergic activity, since all target compounds were less active than haloperidol. These 
studies provide a pharmacological basis for future research on these new compounds devoid of ataleptogenic activity. 
Introduction 
Since the discovery of chlorpromazine as an effective 
antipsychotic agent, large numbers of potential neurolep 
tics have been synthesized. Despite this intense research 
activity, there are still relatively few structurally distinct 
classes of drugs with clinically confirmed antipsychotic 
activity. The butyrophenones, whose prototype is halo- 




While neuroleptic drugs continue to be the best form 
of treatment for schizophrenia, they possess two major 
disadvantages. First, one-third of patients suffering from 
this disorder do not respond to neuroleptic treatment. 
Second, almost all existing neuroleptics produce extrapy- 
ramidal side effects (EPS a short-term parkinsonismlike 
condition caused by dopamine receptor blockade), tardive 
dyskinesia (a syndrome of involuntary movements that has 
been linked to hypersensitivity of brain dopamine recep- 
tors after long blockade), and hyperprolactinaemia (caused 
by blockade of pituitary dopamine receptors). Efforts have 
therefore been made to find drugs with greater clinical 
efficacy and/or reduced propensity to produce EPS. Drugs 
which possess this clinical profile have been termed 
‘atypical antipsychotics”. Cinuperone (2)2 and setoperone 
(3)a are two atypical antipsychotics belonging to the bu- 
tyrophenone group which have been developed in the last 
years. 
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In earlier papers4$ we have reported the potential neu- 
roleptic activity of 2- and 3-(aminomethyl)tetralones 4 and 
5, where the Ra represent simple amine substituents. 
These compounds are semirigid variants of the general 
neuroleptic structure Ar-C,-N. 
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We have also studied the a-blocking and antidopami- 
nergic activity of compounds 5 in isolated rat vas deferens, 
finding that pA2 values increase with the size of the amine 
moiety? These results have prompted us to synthesize 
derivatives 14-17 and to investigate their potential anti- 
dopaminergic activity. 
Interestingly, compounds 14 have two butyrophenone 
pharmacophores, one semirigid and the other flexible, 
while compound 15 combines a semirigid %(amino- 
methy1)tetralone fragment with a benzoylpiperidine 
moiety.’ 
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3-(Aminomethyl)tetralones as Analogues of Butyrophenone 
Table I. &(Aminomethyl)-yphenylbutyric Acids, Methyl Esters 
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compd R N method % yield mp, OC solvent 
1 Oa H 













179-183" EtOH anhyd 
179-183" EtOH anhyd 
200-2026 MeOH-EhOe 
167.5-170" EtOH-EhO 
AcOEt-EtOH 53 149-151' 
13 H NZNQ B 77 190-192' n-PrOH 
CH,O 
a Hydrochloride. *Oxalate. e Washed. 
Table 11. 3-(Aminomethyl)-l-tetralones 
compd R N % yield mp, OC solvent formula 
14a H 37 165-166" EtOH anhyd 
14b F 43 260.4-262b n-PrOH-H20 CmHasF2N202C3H802.2HBr 
16 ND!!+ 
50 135-136' cyclohexane C2.3H24FN02 
16 N- 33 154-156d Et20d C22HsN02.HCl 
17 NZNQ 65 217-218.8 i-PrOH C22HHN202.2HCl 
CH,O 
Maleate. Hydrobromide. e Base. Washed. 
Results and Discussion 
Chemistry. The general synthetic strategy followed in 
preparation of these compounds is shown in Scheme I. 
Arylbutyrolactones 7a,b were prepared by a method pre- 
viously described for the unsubstituted compound,B hy- 
droxymethylation of the 8-aroylpropionic acids followed 
by lactonization to aroylbutyrolactones 6a,b and subse- 
quent reduction of the carbonyl group. Reaction of 7a,b 
with hydrogen bromide in acetic acid afforded unstable 
bromo acids 8a,b, which upon ring closure with poly- 
phosphoric acid were converted to 3-(bromomethyl)-l- 
tetralones 18a,b, whose structures were established by 'H 
NMR. In the nucleophilic reactions with amines, com- 
pound 18s invariably gave the elimination product 34-  
benzobicyclo[4.4.0]heptan-2-one (19a) instead of the de- 
sired substituted derivative. The structure of cyclo- 
propyltetralone 19a, which has been prepared by van 
Tamelen et al! and Julia et al. 'O by alkaline treatment of 
~~ 
(8) Rothe, J.; Zimmer, H. J.  Org. Chem. 1969,24, 686. 
(9) Tamelen, E. E.; McNary, J.; Lomitzo, F. A. J.  Med. C h m .  SOC. 
1967, 79, 1231. 
(10) Julia, S.; Bonnet, Y .  Bull SOC. Chim. France. 1967, 1340. 
the tosylate of 3-(hydroxymethyl)-l-tetralone, was con- 
firmed by analytical and spectral data. 
Several attempts were made to block the carbonyl group 
of (bromomethy1)tetralones 18. It  was not possible to 
obtain the ethylene ketals, and though the ethylene di- 
thioketals 20 were obtained by standard procedures in 70% 
yield, subsequent attempts at nucleophilic substitution 
were unsuccessful. In the end, the final products 14-17 
(Table 11) were obtained in good yields by substitution with 
methyl esters 9 and subsequent cyclization of the resulting 
amino esters 10-13 with PPA (Table I). 
p-Fluoro-4-(N-piperazinyl)butyrophenone (22) was 
prepared by direct alkylation of piperazine with a large 
excess of w-chloro-p-fluorobutyrophenone in methyl iso- 
butyl ketone or, better, by alkylation with the ethylene 
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a (R=H) 
b (R=F) 
Table 111. Inhibition Constants (pKi) at Dl and D2 Receptors and Group Toxicity Antagonism 
PKi: M Dzb group' toxicity confidence 
compd [SH]spiperone [sH]SCH-23390 selectivity antagonism limit 
halop 8.30 7.01 1.29 0.020 0.0054085 
16a 7.60 6.42 1.18 0.251 0.133-0.473 
14b 7.11 6.04 1.07 0.053 0.016-0.181 
15 7.68 6.49 1.19 0.055 0.014-0.215 
16 7.13 6.13 1.00 
17 8.19 5.87 2.32 0.349 0.137-0.892 
OResults represent the mean of at least four inhibition curves constructed with each drug. The mean standard error of Ki values was 
1O-18%. bD2 selectivity: values were calculated as pKi[sH]spiperone minus pKi[sH]SCH-23390. Results correspond to EDw expressed in 
"3. 
Pharmacology has usually been ascribed to their relatively well-known 
The existence of two types of dopamine receptors is &-mediated effects, though it has recently been reported 
widely accepted.12 D1 receptor stimulation leads to in- that a selective D1 antagonist, SCH-23390 (23), also has 
creased adenylate cyclase activity, while D2 receptors me antipsychotic activity." 
either not coupled or are negatively coupled to this en- In the work described here possible interaction of the 
zyme.19-16 The antipsychotic activity of neuroleptic drugs ~ m P o m h  Synthesized with DA recePbm and a-rmePbm 
(11) The alkylation of N-(ethoxycarbony1)piperazine and w-chloro- 
p-fluorobutyrophenone and subsequent decarbethoxylation in 
an alkaline medium gives p-ethoxy-4-(N-piperazinyl)butyro- 
phenone in accordance with the results obtained by Rajsner et 
al.: Rajsner, M.; Metysova, J.; Nemec, J.; Protiva, M. Collect. 
Czech. Chem. Commun. 1975,40, 1218. 
(12) Kebabian, J. W.; Calne, D. B. Nature 1979,277,93. 
(13) Kebabian, J. W.; Petzold, G. L.; Greengard, P. Proc. Natl. 
Acad. Sci. U.S.A. 1972, 69, 2145. 
(14) Stoof, J. C.; Kebabian, J. W. Nature 1981,294,266. 
(15) Cooper, D. M. F.; Bier-Laning, C. M.; Halford; M. K.; Ahlija- 
nian, M. K.; Zahniser, N. R. Mol. Pharmacol. 1986,29, 113. 
(16) Iorio, L. C.; Barnett, A,; Leitz, F. H.; Houeer, V. P.; Korduba, 
C. A. J. Pharmacol. Exp. Ther. 1983,226,462. 
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Figure 1. Apomorphine (1 mg/kg sc) was injected into the 
animals 30 min after the administration of the vehicle (C), hal- 
operidol (H), or compounds (2 mg/kg ip). Stereotyped behavior 
was monitored every 10 min for 30 min, after the injection of 
apomorphine. Results are means f SEM of the scores of six 
animals. Significant difference vs controls: * p  < 0.05, **p < 0.01 
(Student’s t test). 
was investigated “in vivo” by studying their antagonism 
of (+)-amphetamine group toxicity and apomorphine-in- 
duced stereotyped behavior and catalepsy in mice and “in 
vitro” by studying ligand binding and their effects on 
dopamine- and norepinephrine-induced contractions of 
isolated rat vas deferens. 
Blockade of (+)-amphetamine lethality in aggregated 
mice (group toxicity) is a recognized measure of neuroleptic 
a~tivity.~’-~~ In this study compounds 14b and 15 afforded 
greatest protection against group toxicity, though with 
ED,’s greater than that of haloperidol (Table 111). 
In the antagonism to apomorphine the activity of com- 
pound 15 was at all times postadministration (p.a.) similar 
to just slightly less than that of haloperidol. None of the 
compounds studied induced catalepsy at dosages in the 
range 2-8 mg/kg i.p. (data not shown), and since at this 
dosage level they failed to protect against eserine (data not 
shown), this absence of cataleptogenic activity cannot have 
been due to concomitant anticholinergic activity. Their 
effects in these assays designed to test activity in the 
striatum (the catalepsy test and possibly the antistereo- 
typing test) are nevertheless somewhat contradictory when 
considered in the light of previous studies, for while their 
lack of cataleptogenic activity suggests that they do not 
block striatal dopaminergic receptors, whose blockade by 
neuroleptics has been reported to cause catalepsy in ex- 
perimental animalsmt21 and extrapyramidal symptoms in 
man,22 their antagonism of apomorphine suggests that they 
may, the induction of stereotyped activity by apomorphine 
having been related by several authors to the striatal do- 
paminergic This possible contradiction would 
Table IV. Effects of (Aminomethy1)tetralones on NE- and 
DA-Induced Contraction of Isolated Rat Vas Deferens 
pA2 values SEM 
compd against NE against DA 
haloperidol 6.99 & 0.08 7.40 0.15 
14a 6.75 0.12 7.27 & 0.28 
15 7.08 * 0.11 7.45 0.14 
17 6.76 * 0.18 7.18 0.21 
be resolved either if the dopaminergic mesolimbic system 
as well as the nigrostriatal pathway were involved in the 
induction of stereotyped behavior by apomorphine (indeed, 
McKenzie= claimed that only the nucleus accumbens was 
involved in this response) or if the tetralone dosages used 
in this study, though sufficient to antagonize apomorphine, 
were insufficient to elicit a cataleptic response. Whether 
or not higher tetralone dosages would be cataleptogenic, 
the existence of a dosage range for which their neuroleptic 
effects are not associated with catalepsy in mice suggests 
that it might be possible to use them in man as selective 
antipsychotics lacking extrapyramidal side effects (Figure 
1). 
Table I11 summarizes the results on binding to striatal 
dopamine receptors. All the new compounds potently 
displaced [3H]spiperone binding to striatal D2 receptors 
and moderately inhibited the binding of [3H]SCH-23390 
to striatal D1 receptors, with Ki values in the nanomolar 
and micromolar ranges, respectively. Compound 17 has 
the greatest affinity for D2 receptors and the least for D1 
receptors, and was thus the most D2 selective. 
Antidopaminergic activity was also investigated by 
measuring the inhibition of dopamineinduced contractions 
of isolated rat vas deferens which may be mediated by 
postsynaptic D2 or cyreceptor The fact 
that for every antagonist (haloperidol or the new com- 
pounds) the pA2 values for norepinephrine and dopamine 
were practically the same (a result also reported for hal- 
operidol by Leedham and PennefatherFl though not by 
Simon and Van Maanen32) strongly suggests that both 
agonists bind to the same receptors in rat vas deferens. 
Since for haloperidol the pA2 values are unchanged under 
experimental conditions blocking 8-adrenoceptors (by 
addition of propranolol), reuptake of catecholamines by 
neutrons (by addition of cocaine), and extraneuronal up- 
take (by addition of 8-estradiol)F3 it seems likely that 
norepinephrine and dopamine both bind to the al-recep- 
tors to which norepinephrine is already30 known to bind 
in this tissue. The pharmacological activity of the new 
compounds in rat vas deferens would thus consist in ad- 
renergic blocking activity; the hypothesis that the thera- 
peutic effects of antipsychotic drugs are mediated largely 
through noradrenergic blockade has been reassessed, and 
several lines of evidence now suggest that antagonism of 
al-noradrenergic receptors may contribute to the thera- 
Burn, J. H.; Hobbs, R. Arch. Znt. Pharmacodyn. Ther. 1958, 
113, 290. 
Greenblatt, E. N.; Lippa, A. S.; Osterberg, A. C. Arch. Znt. 
Pharmacodyn. Ther. 1978,233, 107. 
Press, J. B.; Hofmann, C. M.; Eudy, N. H.; Day, I. P.; Green- 
blatt, E. N.; Safk, s. R. J .  Med. Chem. 1981,24, 164. 
Janssen, P. A. J.; Niemegeem, C. J.; Schellekens, K. H. Arz- 
neimittel-Forsch (Drug Res.) 1965, 15, 104. 
Stille, G.; Lauener, H.; Eichenberger, E. Farmaco, Ed. Pr. 1971, 
26, 603. 
Sayem, A. C.; Burki, H. R. J.  Pharm. Pharmacol. 1976,28,252. 
Costall, B.; Furtune, D. H.; Hui, S. G.; Naylor, R. J. Eur. J .  
Pharmacol. 1980,63, 347. 
Joyce, J. N. Neuroeci. Biobehau. Reu. 1983, 7, 227. 
Robertaon, A.; MacDonald, C. Eur. J .  Pharmacol. 1988,109, 
81. 
Ogren, S. 0.; Hall, H.; Kohler, C.; Magnusson, 0.; Sjostrand, 
S. E. Psvchonharmacoloav 1986.90, 287. 
Vaccherj, A.. Dall’Olio, Ry; Gandolf;, 0.; Roncado, P.; Mon- 
tarano, N. Psychopharmacology 1987,91, 394. 
McKenzie, G. M. Psychopharmacology 1972,23, 212. 
Badia, A.; Bermejo, P.; Jane, F. J.  Pharm. Pharmacol. 1982, 
34, 266. 
Han, Ch.; Abel, P. W.; Minneman, K. P. Nature 1987,329,333. 
Leedham, J. A.; Pennefather, J. N. Br. J .  Pharmacol. 1982,77, 
293. 
Simon, A.; Van Maanen, E. F. Arch. Znt. Pharmacodyn. 1976, 
222, 4. 
Loza, M.; Orallo, F.; Cadavid, I.; Verde, I.; Gab, A,; Calleja, J. 
M. Proc. XZX Congr. Znt. SOC. Pharm. hiediterran& Latine 
(Lyon 1990). In press. 
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peutic effects of antipsychotic drugsa (Table IV). 
The antipsychotic activity of neuroleptics correlates well 
with their ability to block D2 receptors,ss but not with Dl 
blockade? the performance of neuroleptics in behavioral 
testa is accordingly generally attributed solely to their 
D2-blocking ability,98 though research carried out since the 
discovery of selective D1 agonist and 
suggests that D1 receptors too may mediate the effects of 
neuroleptics on behavior, and possibly their clinical effect 
also.- This may explain the differences between the 
relative potencies of the compounds studied in the 'in 
vivo" and binding experiments; compound 17, the most D2 
selective, was the least effective "in vivo*, indicating the 
possible contribution of both D1 and D2 receptors to the 
antipsychotic activity. 
In conclusion, all the tetralones tested in this study 
proved to posseas antipsychotic activity at dosages at which 
no cataleptic effects were observed. The most active were 
compounds 14b and 15, both of which have two butyro- 
phenone pharmacophores, one the semirigid (amino- 
methylltetralone moiety and the other a flexible linear 
butyrophenone moiety (14b) or a semirigid benzoyl- 
piperidine fragment (15). However, since all the new 
compounds were less active than haloperidol, their tet- 
ralone moiety may not be essential for their neuroleptic 
activity. 
Experimental Section 
Chemistry. Melting points were determined with a Kofler 
hot-stage instrument and with a Gallemkamp capillary melting 
point apparatus and are uncorrected. Proton magnetic resonance 
spectra were obtained with a Varian FT-80 (80 MHz) or a Bruker 
WM-250 (250 MHz) with tetramethylsilane as an internal 
standard. Infrared spectra were recorded with a Perkin-Elmer 
297 spectrometer. Mass spectra were obtained with a Varian 
MAT-711 (70 eV) apparatus. Elemental analysea were performed 
in a Perkin-Elmer 240 apparatus at  the Micronalyses Service of 
the University of Santiago de Compostela (Spain), and values are 
within 0.4% of the theoretical compositions. 
4-(N-Piperazinyl)-p-fluorobutyrophenone (22). Method 
A. To a solution of 12.87 g (149 mmol) of anhydrous piperazine 
in 75 mL of methyl isobutyl ketone was added 5.0 g (25 mmol) 
of w-chloro-p-fluorobutyrophenone dropwise. The solution was 
refluxed for 12 h. The solvent was removed under reduced 
pressure, the solid residue was treated with 10% HCl, and the 
resulting acidic solution was washed with ethyl acetate, made 
alkaline with aqueous sodium hydroxide solution, and extracted 
with methylene chloride. The organic extract was washed with 
water and dried (Na#OJ and the solvent was removed 'in vacuo" 
to yield 5.38 g (86%) of 22 as an oil which solidified on standing. 
6.93-6.90 (d, 2 H, o-PhF), 2.99-2.91 (m, 6 H, piperazino C-2 and 
Mp: 90-93 "C. 'H NMR (CDCla): 6 7.95-7.91 (d, 2 H, 0-PhCO), 
Cortizo et al. 
C-6, CHzCO), 2.58-2.56 (m, 4 H, piperazino (2-3 and C5), 247-242 
C, H, N. 
Method B. To a aolution of 2.10 g (24 mmol) of anhydrous 
piperazine in 7 mL of methyl isobutyl ketone was added 1.0 g (4 
mmol) of 4-chloro- 1,l- (ethylenedioxy) - 1- (4-fluorophenyl) butane 
in 3 mL of methyl isobutyl ketone dropwise. The solution was 
refluxed for 12 h. The solvent was removed under reduced 
pressure and the residue was dissolved in CHzClz, washed with 
water to neutral pH, and dried (NazS04). The solvent was re- 
moved to leave 1.1 g (92%) of 4-piperazinyl-l,l-(ethylenedi- 
oxy)-l-(4-fluorophenyl)butane, which was used for the following 
reaction without further purification. 
A solution of 1.1 g (3.4 mmol) of the ethylene ketal and con- 
centrated HC1 (2 mL) in methanol (30 mL) was refluxed for 2 
h. The methanol was removed under reduced pressure and the 
residue was dissolved in water, made alkaline with aqueous am- 
monia, and extraded with CH2C12. The organic layer was washed 
with water and dried (NaaO,). The solvent was removed by 
evaporation under reduced pressure to yield 0.77 g (83%) of 22. 
8-(Bromomethy1)-y-phenylbutyric Acid, Methyl Ester 
(9a). To a stirred solution of 11.05 g (0.062 mol) of 7 in 17 mL 
of glacial acetic acid at 0 "C was added 20 mL of 33% HBPAcOH 
dropwise. After 15 min at  room temperature, the solution was 
heated at  80 "C for 4 h. After cooling, the reaction mixture was 
poured into ice-water and extracted with chloroform. The 
chloroform solution was washed several times with water and dried 
(Na$04), and the solvent evaporated to afford 15.16 g (94%) of 
8. 
Methyl ester 9a (R = H) was obtained as usual using a solution 
of CHzNz in ether. Bp: 116-120 "C (0.2 mmHg). 'H NMR 
(CDClJ: 6 7.32-7.21 (m, 5 H, Ar), 3.68 (e, 3 H,OCHJ, 3.53-3.40 
(m, 2 H, CH2-Br), 2.72-2.45 (m, 5 H, aliphatic). Anal. 
(CIzHl6BrO2): C, H. 
Compound 9b (R = F) was prepared by the same procedure 
as 9a, using the appropriate lactone, to give quantitative yields. 
Bp 130-135 "C (0.15 mmHg). Anal. (C1zH14BrFOz): C, H. 
3-(Bromomethyl)-l-tetralone (18a). To 196.5 g of well-stirred 
polyphosphoric acid at 60 "C was slowly added 13.10 g (0.05 mol) 
of crude 8a, after which the temperature was increased to 120 
"C. After 2 h, the reaction mixture was poured into ice-water 
and extracted with ether. The organic extracts were washed 
several times with water and dried (NazS04), and the solvent 
evaporated 'in vacuo". The oily residue was distilled (bp 146 "C, 
0.5 mmHg) to yield the desired product, which solidified i"e- 
diately and was recrystallized from heptane to afford 18a (9.25 
7.36-7.28 (m, 2 H, C-5 and (2-71, 3.55-3.43 (m, 2 H, CHzBr), 
3.15-2.99 (m, 1 H, HCHPh), 2.57-2.46 (m, 2 H, HCHCO, CH). 
MS: m / z  (relative intensity) 238-240 M+ (100). Anal. 
(CIIHI1BrO): C, H. 
Compound 18b was prepared similarly to Ma, using 8b as 
starting product (80%). Bp: 150 OC (0.1 mmHg). 'H NMR 
(CDClJ aromatic 'H: 6 8.07-8.01 (m, 1 H, C-8), 7.07-6.95 (m, 
2 H, C-5 and C-7). Anal. (CI1Hl,,l3rFO): C, H. 
8-(Aminoethyl)-y-phenylbutyric Acids, Methyl Esters 
(10-13). General Pmdures: Method A. To a solution of 
the appropriate amine (1.9 m o l )  in anhydrous benzene (3 mL) 
was added B(bromoethy1)-r-phenylbutyric acid methyl ester (0.95 
mmol), in anhydrous benzene (1 mL). After 14 h of refluxing the 
resulting precipitate was removed by filtration and discarded, and 
the solvent was removed from the fitrate under reduced pressure. 
The resulting oil was dieeolved in ether and treated with a solution 
of HC1 in ether to precipitate the salt, which was collected by 
filtration and recrystallized (Table I). 
Method B. To a solution of the appropriate amine (8.4 "01) 
in methyl isobutyl ketone (80 mL) were added anhydrous Na&Os 
(2.96 g) and KI (0.046 g) followed by B-(bromomethyl)-y- 
phenylbutyric acid methyl ester (8.4 mmol) in methyl isobutyl 
ketone. This mixture was refluxed for 20 h. Inorganic salts were 
filtered, and the solvent was removed under reduced pressure. 
The resulting oil was dieeolved in chloroform, washed several times 
with water, and dried (Na804). The chloroform was removed 
under reduced pressure to afford the desired aminomethyl ester 
(Table I). Anal.: C, H, N. 
(t, 2 H, CH,N), 1.96-1.90 (t, 2 H, CCHzC). Anal. (C14H@'I20): 
g, 76%). Mp: 45-47 OC. 'H NMR (CDCla): 6 8.02 (dd, J7.61 = 
1.38 Hz, 1 H, C-8), 7.54-7.48 (dt, J7.a = 1.47 Hz, 1 H, C-6). 
(34) Cohen, B. M.; Lipinski, J. F. Life Sci. 1986, 39,2571. 
(35) Seeman, P.; Chau-Wong, M.; Ted-, J.; Wong, K. Proc. Natl. 
Acad. Sci. U S A .  1975, 72, 4376. 
(36) Seeman, P.; Grigoriadea, D. E.; Niznik, H. B. Drug Deo. Res. 
1986, 9, 63. 
(37) Seeman, P. Synapse 1987,1, 133. 
(38) Perontka, S. J.; Snyder, S. H. Am. J.  Psychiatry 1980,173,12, 
(39) Hyttel, J. Eur. J .  Pharmacol. 1983,91, 153. 
(40) Chrietensen, A. V.; Amt, J.; Hyttel, J.; h e n ,  J. J.; Svendsen, 
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3- (Aminomethy1)tetralones as Analogues of Butyrophenone 
3-(Aminomethyl)-l-tetralonm (14-17). General Procedure. 
To the appropriate aminomethyl ester was slowly added (3.6 
"01) 32 g of well-stirred polyphosphoric acid at 90 OC and the 
temperature was raieed to 130 OC. After 5 h the reaction mixture 
was poured into ice-water and stirred to obtain a total solution, 
which was then made alkaline with 5 N NaOH and extracted with 
C12CH1. The organic phase was washed several times with water 
to neutral pH and dried (NafiO,), and the Cl,CH2 was removed 
"in vacuo" to afford the desired 3-(aminomethyl)-l-tetralone 
(Table 11). Anal.: C, H, N. 
'H NMR (CDClJ data for 146: 6 8.03-7.97 (m, 3 H, C-8, 
0-PhCO), 7.71-7.44 (m, 1 H, C-6), 7.33-7.25 (m, 2 H, C-5 and C-7), 
7.17-7.09 (m, 2 H, o-PhF), 3.11-2.31 (m, 19 H), 1.96-1.91 (m, 2 
H, CHzCH2CO). lab  (aromatic lH): 6 8.04-7.99 (m, 3 H, C-8, 
o-PhCO), 7.38-6.92 (m, 4 H, C-5, C-7, o-PhF). 15: 6 8.07-7.94 
(m, 3 H, (2-8, o-PhCO), 7.49-7.45 (m, 1 H, C-6), 7.34-7.26 (m, 2 
H, C-5 and C-7), 7.17-7.10 (m, 2 H, o-PhF), 3.20-2.67 (m, 6 H, 
aliphatic), 2.45-2.11 (m, 6 H, (CH&N), 1.89-1.81 (m, 4 H, pi- 
peridino, c -3  and c-5). 1 6  6 8.04-8.01 (m, 1 H, C-8), 7.48-7.19 
(m, 8 H, aromatic), 3.16-2.29 (m, 15 H, aliphatic). 1 7  6 8.07-8.01 
(m, 1 H, C-8), 7.52-7.49 (m, 1 H, C-6), 7.34-7.27 (m, 2 H, C-5 and 
C-7), 7.26-6.84 (m, 4 H), 3.86 (8, 3 H, OCH& 3.16-2.34 (m, 15 
H, aliphatic). 
Pharmacology. "In Vivo" Experiments. These experiments 
were peformed in a thennostated room (22 f 1 OC) with a 12/12 
h light/dark cycle (8.00-20.00). All were carried out at the same 
time of day in order to avoid variations caused by circadian 
rhythms. Male albino mice (Charlee River CD.1) weighing 26 
3 g were used throughout. Doses of test compounds, haloperidol, 
apomorphine, (+)-amphetamine, and eserine were prepared im- 
mediately before administration. 
In the group toxicity antagonism test, the new compounds or 
haloperidol (0.25,0.5, 1, and 2 mg/kg) were injected ip 30 min 
prior to (+)-amphetamine (dose 15 mg/kp ip) in volumes of 0.01 
mL/body weight; control groups were administered an equal 
volume of vehicle. After the first administration, the mice were 
placed into groups of 10 in circular cages 20 cm in diameter, 
without food or water; the death rate 24 h after administration 
of (+)-amphetamine was recorded. Group toxicity antagonism 
is expressed as EDm (mg/kg), which was calculated as per 
Litchfield and Wilcoxon.'B 
Catalepsy was tested in five-mice groups 30 and 60 min after 
administration of saline solution, haloperidol, or one of the com- 
pounds under investigation (six groups for each substance). The 
mice were placed with their forepaws on one horizontal wire and 
their hindpaws on another 6 cm away and 2 cm lower; those 
remaining in this position for over 30 s were considered cataleptic. 
In the teat of antagonism to apomorphine-induced stereotyped 
behavior six-mice groups were treated with 1 mg/kg (sc) of 
apomorphine 30 min after administration of 2 mg/kg (ip) of the 
compounds, haloperidol, or saline solution, and during the fol- 
lowing l/? h stereotypes were scored every 10 min with the fol- 
lowing scale: 0, absence of stereotypes; 1, some stereotyped 
movement shown; 2, intense smelling, with mastication and licking 
periods, and 3, large periods of mastication and licking, usually 
with mice climbing on the wall of the cage." 
To test ability to protect against a lethal dose of eserine (2 
mg/kg ip), groups of 10 mice were treated ip 30 min before eserine 
injection, with vehicle, atropine (4 mg/ kg), haloperidol, or the 
new compounds (2-8 mg/kg). The mice were placed in individual 
cages and the dead were counted 24 h after injection of eserine. 
Vas Deferens Assays. Male SpragueDawley rata (25&300 
g) were killed by a blow on the head. The vas deferens was 
diseected free from adhering tissue, removed, and suspended in 
a 10-mL tissue bath containing Krebs solution (composition in 
m M  NaCl, 118; KCl, 4.7; MgS04.7H20, 1.2; CaC12.2H20, 2.5; 
KH2P04, 1.2; NaHCOS, 25; g l u m ,  11) maintained at 37 OC and 
gassed with a mixture of 95% 02 and 5% COD After an equil- 
(46) Tallarida, R. J.; Murray, R. B. Manual of Pharmacologic 
Calculations with Computer Programs. Springer-Verlag: New 
York, 1987. 
(47) C&, L.; Chermat, R.; Cuenca, E.; Simon, P. Arch. Farmacol. 
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ibration period of at least 1 h under 0.8 g of resting tension, 
cumulative concentration-reaponse curvea of isotonic contractions 
induced by an agonist (norepinephrine or dopamine) were ob 
tained by the method of Van Rossuma before and after 5 min 
of exposure to the test compounds. All values were expressed 
as mean * SEN. pA2 values were calculated as per Arunlakshana 
and Schild,'s log(dose ratio - 1) being calculated at three an- 
tagonist concentrations, with four replicate experiments per- 
formed. 
(-)-Norepinephrine bitartrate and 3-hydroxytyramine hydro- 
chloride were obtained from stock solutions (10 mM) in distilled 
water containing sodium bisulfite (1%) and kept frozen (-20 OC). 
Solutions of haloperidol and the test compounds were prepared 
in distilled water immediately before use. The chemicals used 
for the preparation of the Krebs solution were of analytical grade. 
Binding Assays. Male Wistar rats weighing 250-300 g were 
killed by cervical dislocation and decapitation. Both striata were 
quickly dissected on a cold plate, weighed, and stored at -20 "C 
until assayed. 
For determination of [SH]spiperone binding to membrane 
preparations, tissue was homogenized with a Polytron (setting 
6 for 5 s) in 50 vol of ice-cold 50 mM Tris HC1 (pH 7.4) and 
centrifuged at 4oooOg for 10 min in a Sorvall centrifuge at 4 OC. 
The pellet was resuspended and the process repeated. The final 
pellet was resuspended in 200 vol of 50 mM Tris HCl buffer 
containing 120 mM NaCl. Aliquota (200 pL) of the final BUS- 
pension were incubated with 25 pL of displacing agent or ita 
vehicle and 25 pL of a solution of [%]spiperone. For equilibrium 
saturation analysis, six ligand concentration from 0.05 to 1 nM 
were used. Nonspecific binding was defined by addition of 1od 
M of (+)-sulphide. For determinations of the ICw values of drugs 
to displace [Wlspiperone (0.25 nM) binding at least six ascending 
concentrations of each drug were included in the assay ( 1 ~ - 1 0 4  
M). All samples were examined in triplicate at each ligand or 
displacing drug concentration. Samples were incubated for 10 
min at 37 OC. The reaction was terminated by rapid vacuum 
filtration through Whatman GF/C filters, which were washed with 
3 x 5 mL of cold buffer. 
For the determination of [%]SCH-23390 binding to membrane 
preparations, paired striata were homogenized in 200 vol of 50 
mM Tris HC1 buffer and centrifuged at lOOOg for 10 min, and 
the supernatant was centrifuged at 2oooOg for 10 min. The pellet 
was resuspended and the process repeated. The final pellet was 
resuspended in 50 mM Tris HCl containii 120 mM NaCl, 5 mM 
KC1, 2 mM CaCl,, and 1 mM MgCl2. Saturation curves were 
constructed with six ligand concentrations from 0.15 to 2.5 mM. 
Nonspecific binding was determined by addition of unlabeled 
SCH-23390 (lo4 M). Samples were incubated at 25 OC for 30 
min. Inhibition constant (Ki values) were calculated by using the 
Cheng-Prussof equation 
where F is the free concentration of [SH]ligand used, Kd is the 
equilibrium dissociation constant, and ICw is the drug concen- 
tration required to inhibit 50% of specific binding, defined as 
follows: 
Ki = Icm/(l + (F/&)) 
dpm sample - dpm nonspecific binding 
dpm total binding - dpm nonspecific binding x 100 
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